The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC.
S. Tjulandin
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Roche
A. Makhson
No relevant relationships to disclose
J. Gligorov
No relevant relationships to disclose
M. Lichinitser
No relevant relationships to disclose
A. Lluch
Honoraria - Roche
Other Remuneration - Roche
V. Semiglazov
No relevant relationships to disclose
N. Scotto
Employment or Leadership Position - Roche
L. Mitchell
Employment or Leadership Position - Roche
M. Martin
No relevant relationships to disclose